Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

Munderi, P; Walker, AS; Kityo, C; Babiker, AG; Ssali, F; Reid, A; Darbyshire, JH; Grosskurth, H; Mugyenyi, P; Gibb, DM; +2 more... Gilks, CF; DART/NORA trial teams; (2010) Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV medicine, 11 (5). pp. 334-44. ISSN 1464-2662 DOI: https://doi.org/10.1111/j.1468-1293.2009.00786.x

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1111/j.1468-1293.2009.00786.x

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar